Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Mylan Gets Expert Panel Go-Ahead For Pretomanid In India

Thu, 02/13/2020 - 6:13pm

Tuberculosis drug pretomanid gets endorsement, with Phase III trial waiver, from a key expert panel that advises India's drugs regulator...

      Related Stories 

Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group

Thu, 02/13/2020 - 2:05pm

Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor...

      Related Stories 

Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer

Thu, 02/13/2020 - 7:10am

An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with...

      Related Stories 

NICE Rejects Keytruda/Inlyta Combo First-Line In RCC

Thu, 02/13/2020 - 6:49am

The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body...

      Related Stories 

Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co.

Thu, 02/13/2020 - 4:52am

Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines...

      Related Stories 

Allovir Gains PRIME Status For Anti-Virus T-Cell Therapy

Thu, 02/13/2020 - 1:14am

Joining the ElevateBio stable last May, the company has now gained priority status in the US and Europe for its...

      Related Stories 

Serum Institute Awaiting GAVI Push For $2 Pneumococcal Vaccine

Wed, 02/12/2020 - 11:27pm

Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal...

      Related Stories 

Ligand Buys Into Ongoing Partnerships With Icagen Deal

Wed, 02/12/2020 - 12:46pm

Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform...

      Related Stories 

Teva Edges Closer To Growth, But With A Big Overhang

Wed, 02/12/2020 - 10:39am

Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved...

      Related Stories 

Pfizer Ends Pact With GlycoMimetics After SCD Failure

Wed, 02/12/2020 - 5:31am

GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a...

      Related Stories 

It’s A Deal, Finally: Dr Reddy’s Snaps Up Wockhardt’s Branded Gx Business

Tue, 02/11/2020 - 11:49pm

Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much...

      Related Stories 

Genexine Counting On Hyleukin-7’s Potential As Versatile I-O Booster

Tue, 02/11/2020 - 4:43pm

Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations...

      Related Stories 

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Tue, 02/11/2020 - 3:33pm

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going...

      Related Stories 

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

Tue, 02/11/2020 - 11:45am

89Bio thinks its Phase II FGF21 analog could prove best-in-class in NASH due to a longer half-life than Bristol’s pegbelfermin...

      Related Stories 

A Positive Outlook For Deals, With Election Year Caveats

Tue, 02/11/2020 - 11:29am

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even...

      Related Stories